TCRαβ/CD3 disruption enables CD3-specific antileukemic T cell immunotherapy.

ABSTRACT: T cells engineered to express chimeric antigen receptors (CARs) against B cell antigens are being investigated as cellular immunotherapies. Similar approaches designed to target T cell malignancies have been hampered by the critical issue of T-on-T cytotoxicity, whereby fratricide or self-destruction of healthy T cells prohibits cell product manufacture. To date, there have been no reports of T cells engineered to target the definitive T cell marker, CD3 (3CAR). Recent improvements in gene editing now provide access to efficient disruption of such molecules on T cells, and this has provided a route to generation of 3CAR, CD3-specific CAR T cells. T cells were transduced with a lentiviral vector incorporating an anti-CD3ε CAR derived from OKT3, either before or after TALEN-mediated disrupti

SUBMITTER: Rasaiyaah J 

PROVIDER: S-EPMC6124532 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature